"Please excuse, yes I am confused.  What study showed the efficacy was 55% with Cardiovascular Disease and 77% with Cardiovascular Disease and Diabetes"

Sidebar, ASSURE and SUSTAIN were the first trials that were combined for MACE post-hoc analysis. Later they threw in ASSERT too. I suggest that you read this post and click on the various links from the paragraph below to catch up.

Although the failure to achieve the primary plaque reduction outcome overshadowed the ASSURE trial, the incidence of major adverse cardiac events (MACE) was a pre-specified secondary outcome in ASSURE (5-point MACE: death, myocardial infarction, stroke, coronary revascularization, hospitalization for ACS or heart failure). In the news release that reported the low-HDL with rosuvastatin responder population, it was noted that apabetalone-treated patients in ASSURE showed a trend for reduced MACE. Then came the post-hoc analyses of the Phase 2 programs that combined either SUSTAIN and ASSURE trials, also published in this Atherosclerosis 2016 paper, or combined ASSERT, SUSTAIN and ASSURE trials. Long story short, apabetalone reduced 5-point MACE in the total population, but even more so if one looks at just the diabetics or just those with elevated baseline hsCRP >2mg/dL as revealed in post-hoc analyses (here and here).